Clinical Trials Logo

Filter by:
  • Recruiting  
  • Page [1] ·  Next »
NCT ID: NCT06332001 Recruiting - Neoplasm Malignant Clinical Trials

Evaluation of a Music and Interaction Intervention on Patient Distress During Whole Body Magnetic Resonance

Start date: December 31, 2020
Phase:
Study type: Observational

This is a randomized controlled trial for the evaluation of the acceptability of Whole-Body-Magnetic Resonance Imaging (WB-MRI) based on music and comunication intervention compared to a standard care condition. Subjects will be randomized into two groups: the experimental group or arm that receives the music and interaction interventions, and the control group or arm that receives a standard care condition.

NCT ID: NCT06331988 Recruiting - Colorectal Cancer Clinical Trials

Microbiome, Immune-system and Tumor Interaction in Colorectal Cancer

MITICO
Start date: July 21, 2022
Phase:
Study type: Observational

Colorectal cancers represent the second leading cause of cancer-related death in the United States Western world. In Italy they represent the second most frequent neoplasm (49,000 cases in 2019). Despite the advancement of surgical techniques and medical therapy programs systemic, it is estimated that approximately 40-50% of colorectal cancers recur after being treated for a limited loco-regional disease. Patients who develop metastases throughout their history clinic have a 5-year overall survival of just over 10%. Adjuvant systemic chemotherapy can reduce the risk of disease recurrence in patients with colorectal adenocarcinomas, however, the standard drugs used to date for this use (fluoropyrimidines and oxaliplatin) have not undergone substantial changes in the last 20 years or so. A crucial point is therefore the need to have more precise information regarding risk factors not only clinical but above all biomolecular on which to base therapeutic choices. It has now become urgent to overcome the T-tumor N-node M- metastasis (TNM) staging, to have more modern knowledge on the factors capable of impacting significantly on the prognosis, influence the real risk of disease recurrence, Identify new prognostic categories and subcategories, therefore being able to predict the clinical benefit of treatments that can be more targeted, personalized and effective. In this panorama it has developed in recent years an ever-growing literature also regarding the role of bacterial flora intestinal (microbiota) in patients with colorectal cancer. In particular, recent discoveries have highlighted the immunoregulatory role of the microbiota in the anti-tumor response. This study aims of evaluating how the molecular characteristics of the tumor, of the infiltrating immune system cells and of the associated intestinal microbiota correlate with the development of colorectal cancer, its progression and response to treatments.

NCT ID: NCT06331806 Recruiting - Clinical trials for Cardiomyopathy Due to Drug

Myocardial Fibrosis Identification in Patients With Anthracycline-induced Cardiotoxicity

Start date: February 22, 2018
Phase: N/A
Study type: Interventional

This is an interventional study for patients who had developed Anthracycline-Induced Cardiotoxicity (AIC) during or after anthracycline-containing therapy, referred to the Cardioncology Unit for heart failure treatment

NCT ID: NCT06331793 Recruiting - Post Operative Pain Clinical Trials

Pulsed Electromagnetic Fields for Analgesia Post Mastectomy

Algocare
Start date: May 9, 2023
Phase: N/A
Study type: Interventional

Study aim is to test AlgoCare, a device that uses the technology PEMF (Pulsed ElectroMagnetic Fields) for the treatment of postoperative pain in oncological breast surgery, in order to demonstrate that the use of Algocare in the postoperative period allows for a reduction in pain intensity in terms of Numerical Rating Scale (NRS) score and use of analgesic drugs.

NCT ID: NCT06331130 Recruiting - Ovary Cancer Clinical Trials

Mesenteric Infiltration in Ovarian Cancer

MIO
Start date: March 1, 2024
Phase:
Study type: Observational

To evaluate if CT features at diagnosis in patients with HGSOC can be used to build an Artificial Intelligence model capable of discerning the pathological involvement of the mesentery, assessing the potential impediments for an optimal debulking surgery and predicting the development of resistance to platinum based chemotherapeutic agents.

NCT ID: NCT06331117 Recruiting - Noonan Syndrome Clinical Trials

Effect of RAS/MAPK Pathway Hyperactivation on Growth' and Bone' Profile of the RASopathies

3776
Start date: April 22, 2021
Phase: N/A
Study type: Interventional

Costello syndrome (CS) and cardio-facio cutaneous syndrome (CFCS) belongs to RASopathies, a group of multisystemic disorders caused by unregulated signalling through the RAS/MAPK pathway, an intracellular signalling pathway regulating multiple processes such as cellular proliferation, differentiation, survival, apoptosis and also contributing to oncogenesis. They share a recognizable facial appearance, aged appearance, growth delay, muscle-skeletal anomalies, heart defects, neuropsychological features, skin and ocular abnormalities, and cancer predisposition. Even though life expectancy of individuals with CS and CFCS has increased in the last years due to the improvement of patients' care and a more effective prevention of comorbidities, some of the most challenging aspects impacting on everyday living such as growth failure, accelerate senescence and skeletal-muscle defects, still need to be fully understood. This statement underlies the need to improve clinical research protocols with more innovative techniques (multi-omics profiling) in order to better understand the effect of RAS/MAPK pathway hyperactivations on different systems and to define possible personalized treatments.

NCT ID: NCT06331013 Recruiting - Prostate Cancer Clinical Trials

CyberKnife Ultra-hypofractionated SBRT for Localized PROStatE cancEr

PRO-SPEED
Start date: February 20, 2023
Phase: N/A
Study type: Interventional

This is a prospective observational study. The study will proceed with the enrollment of 60 patients in 2 years. he aim of the present study is to evaluate effectiveness of ultra-hypofractionated (UH) CyberKnife Stereotactic Body Radiation Therapy treatment on the whole prostate gland plus Simultaneous integrated boost (SIB) to the dominant intraprostatic lesions (DIL(s) in intermediate-unfavourable to high-risk Prostate Cancer (PCa) patients.

NCT ID: NCT06330987 Recruiting - Pregnancy Related Clinical Trials

Fetal Autonomic Nervous sysTem Evaluation

FANTE
Start date: August 13, 2019
Phase:
Study type: Observational

The autonomic nervous system (ANS) is involved in cardiovascular, metabolic and cognitive processes, so its study in the fetus can provide relevant functional diagnostic and prognostic information. In particular, the study of the fetal ANS allows us to understand the degree of nervous maturation reached by the fetus and any developmental disorders that could have an impact on the cardiovascular characteristics of the fetus. The goal of this open-label, non-randomized, prospective observational study is to study the fetal ANS in pregnant women between 23 and 40 weeks of gestation. The objetives are: - To Evaluate Fetal Autonomic Nervous System (FANTE) through the analysis of maternal electrocardiogram (ECG) and others clinical parameters usually used in pregnancy monitoring. - To identify any variations in the fetal ECG in the event of developmental or pathological maternal and/or fetal pregnancy. Participants will be recruited during ultrasound visits, information sessions, and hospitalizations after signing informed consent.

NCT ID: NCT06330454 Recruiting - Knee Pain Swelling Clinical Trials

Painful Total Knee Replacement (TKA) and I-one Therapy

Start date: October 22, 2020
Phase:
Study type: Observational

Arthroplasty operations are very frequent and their number is constantly increasing. The success of prosthetic surgery is linked to surgical factors (prosthesis type, prosthesis design, prosthesis material, surgical hand) and 'biological' factors (inflammation, pain, oedema, impingement). It is well known that important functional limitations may result mainly from an overreaction involving the peri-articular tissues. This is particularly true after total knee arthroplasty (TKA) surgery, during which a large part of the bone tissue and part of the peri-articular tissues (joint capsule, ligaments, synovium) are dislodged or removed. In the days following arthroplasty operations, the presence of a strong local inflammatory component is associated with pain and functional limitation, which usually resolves within a few months; however, it can sometimes take longer, and sometimes result in a chronic, albeit modest, inflammatory condition that lasts for years. There is still a percentage of 11-25% of patients who remain not completely satisfied with the result achieved with prosthetic surgery (Bourne RB). Baker et al. state that 19.8% of patients experience pain one year after arthroplasty (Baker 2007). Beswick et al. report that many patients (10-34%) continue to experience significant pain and functional limitation after arthroplasty even years later (Beswick 2012).

NCT ID: NCT06329739 Recruiting - Parkinson Disease Clinical Trials

Genetics in Parkinson's Disease: Behavioral and Cognitive Outcomes

Start date: December 14, 2021
Phase:
Study type: Observational

The genetic landscape of Parkinson's disease (PD) is characterised by rare high penetrance pathogenic variants causing familial disease, genetic risk factor variants driving PD risk in a significant minority in PD cases and high frequency, low penetrance variants, which contribute a small increase of the risk of developing sporadic PD. This knowledge has the potential to have a major impact in the clinical care of people with PD. The goal of this observational study is to evaluate the impact of genetic mutation on behavior and cognition in PD patients. Patients will be assessed over time using test, questionnaire and standardised clinica scales. An initial assessment and annual follow-up assessments will be carried out for 5 years. Researchers will compare data collected from patients with genetic mutation versus patients without mutation.